Anavex Life Sciences Corp. (AVXL) Financial Statements (2024 and earlier)

Company Profile

Business Address 630 5TH AVENUE
NEW YORK, NY 10111
State of Incorp.
Fiscal Year End September 30
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
MRQ
9/30/2023
9/30/2022
9/30/2021
9/30/2020
9/30/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments143,765151,024149,158152,10829,24922,186
Cash and cash equivalents143,765151,024149,158152,10829,24922,186
Receivables3,5492,7093,1939,1374,8492,643
Prepaid expense    356444 
Other undisclosed current assets      501
Total current assets:147,314153,733152,350161,60034,54225,329
Noncurrent Assets
Regulated entity, other noncurrent assets    16  
Total noncurrent assets:    16  
Other undisclosed assets756653354   
TOTAL ASSETS:148,070154,386152,705161,61634,54225,329
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,57811,61711,06710,3557,3065,040
Employee-related liabilities1,297   
Accounts payable4,2924,3223,8254,7403,9893,523
Accrued liabilities7,2867,2955,9455,6153,3171,516
Deferred revenue917     
Total current liabilities:12,49511,61711,06710,3557,3065,040
Noncurrent Liabilities
Other undisclosed liabilities  917(854)444  
Total liabilities:12,49512,53410,21410,7987,3065,040
Equity
Equity, attributable to parent135,575141,852142,491150,81827,23720,290
Common stock828278766253
Additional paid in capital437,184434,839387,977348,328186,852153,634
Accumulated deficit(301,691)(293,069)(245,564)(197,586)(159,677)(133,397)
Other undisclosed equity, attributable to parent      
Total equity:135,575141,852142,491150,81827,23720,290
TOTAL LIABILITIES AND EQUITY:148,070154,386152,705161,61634,54225,329

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
9/30/2019
Revenues
(Other Income)
    444  
Gross profit:    444  
Operating expenses(51,665)(55,756)50,986(42,001)(31,088)(29,107)
Other undisclosed operating loss   (101,972)   
Operating loss:(51,665)(55,756)(50,986)(41,557)(31,088)(29,107)
Nonoperating income8,6228,2583,3664,3604,8302,894
Gain (loss), foreign currency transaction, before tax(250)(40)(904)(267)126(42)
Interest and debt expense      116
Other undisclosed loss from continuing operations before equity method investments, income taxes    (444) (116)
Loss from continuing operations before income taxes:(43,043)(47,498)(47,619)(37,641)(26,258)(26,213)
Income tax expense(112)(7)(717)(535)(23)(82)
Loss from continuing operations:(43,155)(47,505)(48,336)(38,176)(26,280)(26,295)
Loss before gain (loss) on sale of properties:(48,336)(38,176)(26,280)(26,295)
Net loss:(43,155)(47,505)(48,336)(38,176)(26,280)(26,295)
Other undisclosed net income attributable to parent   358268  
Net loss available to common stockholders, diluted:(43,155)(47,505)(47,978)(37,909)(26,280)(26,295)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
9/30/2019
Net loss:(43,155)(47,505)(48,336)(38,176)(26,280)(26,295)
Comprehensive loss, net of tax, attributable to parent:(43,155)(47,505)(48,336)(38,176)(26,280)(26,295)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: